Methods and compositions comprising a KRASG12C inhibitor and a PD-L1 binding antagonist for treating lung cancer

US12171763B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Marie Evangelista · San Francisco, US
• Mark Merchant · South San Francisco, US
• Jennifer Lee Schutzman · Belmont, US
• Ting-Kun Mark Lin · Mill Valley, US
• Stephanie Royer Joo · San Diego, US
• Sandhya Vinayak Mandlekar · Foster City, US

Key dates

• Filing date: Nov 11, 2021
• Grant date: Dec 24, 2024
• Expiry date: Nov 11, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K16/2827
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).